NSCLC
Conditions
Interventions
None listed
Sponsors
Yokohama City University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Study Selection// Any article written in English language presenting a randomized controlled trial (RCT)is considered eligible. Conference abstracts will be accepted for this study. The study phase is not a factor for exclusion. Patients// Patients with NSCLC will be evaluated, irrespective of cancer stage, pathological subtype, or driver mutation, as long as the patients were candidates for perioperative chemotherapy according to the authors of the original article. Treatment// This study is focused on perioperative chemotherapy, including NAC and AC, regardless of the agents, regimens, and number of cycles used. Cytotoxic agents, molecular targeted therapy (MTT), immune checkpoint inhibitors (ICI), or combinations thereof are acceptable. Any treatment combined with radiotherapy will not be included.
Exclusion criteria
Exclusion criteria: Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoints consist of the correlation between hazard ratios (HRs) of surrogate endpoints and overall survival (OS). The surrogates, namely DFS, RFS, and PFS, will be evaluated collectively for the primary endpoints. DFS, RFS, and PFS will be assessed specifically as part of the subgroup analysis. | — |
Countries
Japan
Contacts
Public ContactNobuyuki Horita
Yokohama City University Hospital Chemotherapy Center
Outcome results
None listed